Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Subscribe To Our Newsletter & Stay Updated
